Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568776 · ClinicalTrials.gov registry record · Phase 2
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
- 20
- Study locations
NCT00568776: Completed Phase 2 study of Alzheimer Disease, sponsored by OPKO Health.
NCT00568776 is a Phase 2 study of Alzheimer Disease that has completed, run by OPKO Health. The registered enrollment target is 353 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568776, a Phase 2 study of Alzheimer Disease, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
Primary Outcome
The NTB assessment is comprised of 9 instruments that measure cognition and executive function. Three of these tests measure immediate memory, next three measure delayed memory, and remaining three assess executive function. The total score is a weighted mean of the nine tests, referred to as the Z-score. Typically, scores range from -3 and 3, with lower scores suggesting greater cognitive impairment.
Conditions Studied
Interventions
- DRUG Placebo Control
- DRUG ELND005
Study Locations (20)
Florida
- Brain Matters Research, Inc. - Delray Beach
- Sunrise Clinical Research, Inc - Hollywood
- Miami Jewish Home and Hospital For The Aged - Miami
- Avision Research Associates, LLC - Miami
- Compass Research, LLC - Orlando
- Roskamp Institute - Sarasota
- Neurology Clinical Research, Inc. - Sunrise
- University of South Florida Suncoast Alzheimer's and Gerontology Center - Tampa
- Premiere Research Institute - West Palm Beach
California
- Margolin Brain Institute - Fresno
- Collaborative NeuroScience Network, Inc. - Garden Grove
- UCLA Alzheimer's Disease Center, Dept. of Neurology - Los Angeles
- UC Irvine Medical Center - Orange
- UCSF Medical Center, Dept. of Neurology - San Francisco
Arizona
- Banner Alzheimer's Institute - Phoenix
- Sun Health Research Institute - Sun City
- University of Arizona, Health Sciences Center, Dept. of Neurology - Tucson
Connecticut
- Yale University School of Medicine, Alzheimer's Disease Research Unit - New Haven
District of Columbia
- Georgetown University Medical Center, Dept. of Neurology - Washington D.C.
Georgia
- Emory University, Dept. of Neurology - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00568776 record still lists
NCT00568776 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo Control is the first listed.
NCT00568776 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00568776 about?
NCT00568776 is a clinical study titled "ELND005 in Patients With Mild to Moderate Alzheimer's Disease". The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
What is the current status of trial NCT00568776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2007-12. Estimated completion is 2010-05.
What conditions does trial NCT00568776 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT00568776?
The interventions under investigation include: Placebo Control (DRUG), ELND005 (DRUG).
Who is sponsoring clinical trial NCT00568776?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00568776 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00568776's enrollment target sits among peer trials
353 72nd of 306 higher than 235 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia